Healthy children can once again receive a booster shot to protect against Haemophilus influenza type b (Hib) disease after the US Food and Drug Administration (FDA) lifted a temporary deferral meant to conserve a shortage in stock.

A nationwide shortage of the important childhood vaccine produced by GlaxoSmithKline (GSK) led to the Centres for Disease Control and Prevention (CDC) recommending temporary deferral of the booster dose for healthy children not at increased risk.

The CDC has now lifted the deferral recommendation and has recommended once again that children receive the booster shot during routine visits.

In addition, the CDC is strongly recommending that all children who missed the booster shot due to the shortage receive a Hib booster as soon as possible.

Supplies of the Hib vaccine received a timely boost in August with FDA approval of GSK’s Hiberix vaccine.